Represents the amortization of capitalized fees paid to a related party.

No definition available.

Name:	inva_AmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of additional preclinical MABA compounds added to the MABA program.

+ References

No definition available.

+ Details

Name:	inva_CollaborationArrangementObligationToDiscoverPreclinicalCompounds
Namespace Prefix:	inva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate for combination products.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential future contingent payments that the entity is eligible to receive.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementContingentPaymentThatEntityCouldEarn
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of registrational and launch-related milestone fee paid under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRegistrationalAndLaunchRelatedMilestoneFeesPaid
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of research reimbursement recognized under the collaborative arrangement by the entity as a result of reduction in research and development expense.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned under collaborative arrangements from upfront payments and contingent payments.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementsRevenue
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the percentage of contingent payments and royalties receivable for sales made by the entity.

+ References

No definition available.

+ Details

Name:	inva_ContingentPaymentsAndRoyaltiesReceivableAsPercent
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of milestone payment which company is entitled to receive.

+ References

No definition available.

+ Details

Name:	inva_EligiblePercentageOfMilestonePayment
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents.

+ References

No definition available.

+ Details

Name:	inva_RoyaltyRevenueFromRelatedPartyNet
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares issued during the period as a result of private placement to a related party.

+ References

No definition available.

+ Details

Name:	inva_StockIssuedDuringPeriodSharesPrivatePlacementToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value stock issued during the period as a result of private placement to a related party, net of issuance cost.

+ References

No definition available.

+ Details

Name:	inva_StockIssuedDuringPeriodValuePrivatePlacementToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=inva_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=inva_TheravanceBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_BifunctionalMuscarinicAntagonistBeta2AgonistMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_LABACollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_GovernanceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements (Details) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
Collaborative Arrangements (Details) $ in Thousands	Oct. 31, 2011 item	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($) shares
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party										$ (13,823)	$ (11,066)	$ (743)
Royalty revenue										53,064	7,351	1,202
Revenue from collaborative arrangements										885	1,082	3,330
Total net revenue		$ 22,836	$ 13,562	$ 10,655	$ 6,896	$ 7,280	$ 999	$ 934	$ (780)	53,949	8,433	4,532
Aggregate purchase price of common stock										$ 6,528	$ 38,095	$ 126,030
Common Stock
Information related to collaborative arrangements
Company's stock purchased by related party (in shares) \| shares										424,000	1,665,000	3,505,000
Aggregate purchase price of common stock										$ 4	$ 17	$ 35
GSK
Information related to collaborative arrangements
Royalties from a related party										66,887	18,417	1,945
Less: amortization of capitalized fees paid to a related party										(13,823)	(11,066)	(743)
Royalty revenue										53,064	7,351	1,202
Total net revenue										$ 53,949	8,433	4,532
Contingent payments and royalties receivable (as a percent)										15.00%
Reimbursement of certain research and development costs to the entity										$ 0	100	500
GSK \| Theravance Biopharma
Information related to collaborative arrangements
Contingent payments and royalties receivable (as a percent)										85.00%
GSK \| MABA
Information related to collaborative arrangements
Potential future contingent payments receivable		$ 363,000								$ 363,000
Percentage of milestone payment										15.00%
Long-acting beta agonist (LABA) collaboration \| GSK
Information related to collaborative arrangements
Revenue from collaborative arrangements										$ 0	0	1,815
Milestone fees paid											220,000
Royalty rate for first level of annual global net sales (as a percent)										15.00%
Annual global sales level used to determine royalty rate										$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)										5.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| Minimum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)										6.50%
Long-acting beta agonist (LABA) collaboration \| GSK \| Maximum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)										10.00%
2004 Strategic alliance \| GSK \| MABA
Information related to collaborative arrangements
Revenue from collaborative arrangements										$ 885	$ 1,082	$ 1,515
Number of preclinical MABA compounds discovered \| item	6
Governance agreement \| GSK \| Common Stock
Information related to collaborative arrangements
Company's stock purchased by related party (in shares) \| shares										424,081
Aggregate purchase price of common stock										$ 6,500